It's fairly standard to have an investment bank representative when you're shopping yourself.
ANDS has been hyping an ANA598 partnership for awhile now. If they were truly drawing legitimate interest from big pharma, I don't think they would need to all of a sudden turn to Lazard for help. This news isn't surprising, however, insofar as the results to date for the drug have been so-so and the drug itself isn't even in one of the HCV classes that most expect to form the backbone of HCV therapy in the future (PIs and/or nukes, not non-nukes).
Market Data 
Markets 
AI
